Keyword: Brii Biosciences
U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.
The deal is part of a broader push by Brii to use some of the $260 million it raised last year to bring new antibiotics to patients.
GlaxoSmithKline veteran Zhi Hong co-founded Brii Biosciences, a biotech with a mission to improve public health in China, in 2018.
Private biotechs raised a record-breaking $16.8 billion in 2018, blowing past the record $12.1 billion set the previous year. Here are the top 10 fundraising rounds—which broke some records themselves and together illustrate what's hot out there in the field.
Brii Biosciences is expanding on existing partnerships and inking a new deal with VBI Vaccines that could be worth up to $128.5 million.
This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.
Bringing innovative, clinically differentiated medicines to Chinese patients.
All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors.